Gandeeva Therapeutics’ Post

Despite ambitious goals, Pear Therapeutics faced go-to-market challenges and revenue difficulties. Now, nearly one year following Pear’s bankruptcy, the company’s assets have been acquired by four prominent players in the industry. What does this mean for DTx? Let's discuss! Join the waitlist for an insightful discussion on: 🔍 Broader implications for the digital health industry. 🚀 Confidence in digital therapeutics technology and future market shaping. 💡 Revenue generation strategies with innovative product lines. Meeting Full. JOIN THE WAITLIST NOW ➡️ https://lnkd.in/g-ujacYw #digitalhealth #digitaltherapeutics #healthtech

Excited to dive into this discussion with such an expert panel, if you are in the bay area next week send me a message to connect!

In a recent interview with China's leading healthcare industry outlet 动脉网 VCBeat, our Partner kan chen, PhD shared the strategy, approach and considerations for Qiming when investing in innovative therapeutics. #QMinsights #Qiminginsights #Chinahealthcare #healthcareinvestment #drugdevelopment 

Thank you, DTx Conference Series for a wonderful DTxEast meeting and for inviting me to chair Day 3. I am so grateful to have had a platform to discuss my 3 main insights from the meeting: - Though the promise of payer reimbursement for prescription digital therapeutics is still largely unrealized, there remains great cause for optimism as we focus on the diversity of other go-to-market strategies including over-the-counter D2C, employers, and value-based care systems. - Digital therapeutics will not fit into a one-size fits all commercialization plan. Different products, with different intended uses, to help different patient populations will require different means to get our products to the patients who need them. - We got into digital therapeutics because we know that only digital interventions have the ability to deliver evidence-based, effective interventions at the scale needed to fit the human demand. We all need to keep that mission, to improve human health and lives, as our north star. #Digitaltherapeutics BehaVR

In this K-Cast episode, Diana Brixner, discusses the level of clinical evidence payers should expect and require from non-prescription digital health tools compared to FDA-approved digital therapeutics! Brixner offers insight as to where the biggest gaps in evidence generation for digital therapeutics come from. Watch here: https://bit.ly/4drOvLE #ManagedCare #DigitalHealth

"If we listen to our sites and leverage existing site platforms, there may not be a need to invest in new technology or vendor services to implement DCTs or hybrid studies... The site-centric approach also decreases complexity and principal investigator (PI) oversight burden." — Noelle Gaskill, Head of Clinical Research Collaborations at Mirati Therapeutics. Read more insights in the ACRP blog > https://bit.ly/3T5ahLX Learn more during Noelle's #ACRP2024 session > https://bit.ly/3T5ahLX #GoForIt #GoForEducation #ClinicalResearch #ClinicalTrials #DecentralizedClinicalTrials #DCTs

Discover how Jess, HR Director at Lucy Therapeutics, leveraged Order.co's real-time spend data and custom reports to optimize cash flow. In this video, she shares insights on staying within budget, crucial for revenue-generating phases. With enhanced tools and visibility, Jess ensures seamless budget management for her team. Watch now to learn more: https://hubs.la/Q02zVNxY0 #budgetmanagement #spenddata #cashflowmanagement

Check out the latest episode of the AMCP Podcast Series - Listen Up! Fantastic discussion with Dr. Scott Whittle on prescription and other digital therapeutics. #ListenUp #pharmacy #pharmacybenefits

👀 Looking for a better way to manage data capture, patient-reported outcomes and consent for your next trial? Follow Swing Therapeutics, Inc.’s lead and work smarter, not harder, with #Medrio #CDMS/ #EDC, #eCOA/ #ePRO, and #eConsent. 💡 https://bit.ly/3rvUFr2